NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has earned an average rating of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $15.67.

Several analysts recently weighed in on NPCE shares. Morgan Stanley raised their target price on shares of NeuroPace from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Wednesday, March 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 price objective on shares of NeuroPace in a report on Thursday, May 9th. Finally, Wells Fargo & Company raised shares of NeuroPace from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $16.00 to $20.00 in a report on Thursday, March 14th.

Insider Transactions at NeuroPace

In other news, major shareholder Orbimed Advisors Llc sold 14,069 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $14.01, for a total transaction of $197,106.69. Following the transaction, the insider now directly owns 3,504,898 shares in the company, valued at $49,103,620.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 525,345 shares of company stock worth $7,583,250. Insiders own 22.20% of the company’s stock.

Hedge Funds Weigh In On NeuroPace

A number of hedge funds have recently modified their holdings of NPCE. Kent Lake Capital LLC grew its position in NeuroPace by 16.8% in the 4th quarter. Kent Lake Capital LLC now owns 670,946 shares of the company’s stock valued at $6,917,000 after buying an additional 96,529 shares during the last quarter. Vanguard Group Inc. grew its position in NeuroPace by 18.3% in the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after buying an additional 75,512 shares during the last quarter. Acadian Asset Management LLC purchased a new position in NeuroPace in the 1st quarter valued at $621,000. Hillsdale Investment Management Inc. purchased a new position in NeuroPace in the 1st quarter valued at $155,000. Finally, Barclays PLC grew its position in NeuroPace by 9,085.6% in the 3rd quarter. Barclays PLC now owns 10,839 shares of the company’s stock valued at $105,000 after buying an additional 10,721 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

NeuroPace Stock Up 2.2 %

Shares of NASDAQ:NPCE opened at $7.00 on Friday. The firm’s 50 day moving average price is $8.96 and its 200 day moving average price is $11.81. The stock has a market cap of $201.39 million, a price-to-earnings ratio of -5.88 and a beta of 1.80. NeuroPace has a fifty-two week low of $3.91 and a fifty-two week high of $18.15. The company has a quick ratio of 5.56, a current ratio of 6.43 and a debt-to-equity ratio of 4.05.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, meeting the consensus estimate of ($0.32). The firm had revenue of $18.12 million for the quarter, compared to analysts’ expectations of $18.12 million. NeuroPace had a negative net margin of 45.61% and a negative return on equity of 173.62%. As a group, equities research analysts predict that NeuroPace will post -1.14 earnings per share for the current fiscal year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.